Current Edition

Europe

Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial

Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 ...
Continue Reading →